MicroRNA-146-5p Promotes Pulmonary Artery Endothelial Cell Proliferation under Hypoxic Conditions through Regulating USP3

Wei Zhang,¹ Yujuan Qi,² and Bo Wu³

¹Department of Cardiac Surgery, Tianjin Chest Hospital, Tianjin, China
²Department of Cardiac Surgery ICU, Tianjin Chest Hospital, Tianjin, China
³Department of Surgery, Tianjin Peace New Century Women and Children’s Hospital, Tianjin, China

Correspondence should be addressed to Wei Zhang; zhangwei2988@hotmail.com

Received 13 October 2021; Accepted 19 November 2021; Published 7 December 2021

Academic Editor: Simona Pichini

Copyright © 2021 Wei Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. MicroRNAs play a pivotal role in the progression of pulmonary hypertension (PAH). Although microRNA-146-5p is specifically expressed in many diseases, but in PAH, its role remains elusive. Patients and Methods. 30 patients with PAH and 20 healthy volunteers in our hospital were enrolled, and their serum samples were extracted for the detection of microRNA-146-5p and ubiquitin specific protease 3 (USP3) expression. In addition, the interaction between microRNA-146-5p and USP3 was examined by luciferase reporting assay. Furthermore, the potential mechanism was explored by cell counting kit-8 (CCK-8), 5-ethynyl-2′-deoxyuridine (EdU), and Western blotting experiments.

Results. It was found that microRNA-146-5p was higher in PAH patients than in healthy volunteers. Meanwhile, in hypoxia-induced human pulmonary artery endothelial cell lines (HPAECs), microRNA-146-5p expression was dramatically downregulated while USP3 protein expression was conversely upregulated. Under hypoxic conditions, microRNA-146-5p mimics was able to prompt the growth of HPAECs. In addition, after overexpression of microRNA-146-5p, luciferase reporting assay revealed a reduced luciferase activity of the reporter gene containing the USP3 3′-untranslated region, and a reduction of USP3 protein expression was also confirmed. However, USP3 overexpression partially attenuated the impact of upregulated microRNA-146-5p on the proliferation capacity of HPAECs.

Conclusions. MicroRNA-146-5p was able to enhance the proliferation ability of HPAEC cells under hypoxic conditions through targeting USP3, suggesting the microRNA-146-5p/USP3 axis may act as a target for PAH treatment.

1. Introduction

Related diseases caused by pulmonary arterial hypertension (PAH) have gradually become a serious public health problem. Hypoxia may lead to pulmonary vasoconstriction and induce PAH, which may lead to pulmonary vascular reconstruction and the occurrence of pulmonary heart disease [1, 2]. Under the current circumstances, it is of great significance to uncover the mechanism of PAH under hypoxia to improve the prognosis, survival rate, and quality of life of patients with pulmonary heart disease induced by chronic hypoxia pulmonary diseases [3, 4]. Some studies suggested that a variety of growth factors can be produced in the lung during hypoxic conditions to stimulate the proliferation of smooth muscle cells, elastic fibers, and collagen fibers in the inner membrane, resulting in pulmonary vascular remodeling [5, 6]. PAH caused by such vascular remodeling may be relevant to a number of mechanisms such as phenotypic changes of pulmonary smooth muscle cells [7, 8].

Among many clinical molecular markers, microRNA (miRNA), due to its small molecular size and wide role, has gradually attracted wide attention from the medical community in recent years [9, 10]. miRNA is a kind of endogenous noncoding single-stranded RNA encoded by endogenous genes with a length of about 22 nucleotides, which plays a significant role in cell differentiation, proliferation, apoptosis, tumor occurrence, and drug efficiency [11, 12]. Recent studies have also demonstrated that
microRNA-146-5p, as a member of miRNA family, is also involved in various stages of cell development, including cell proliferation, apoptosis, and variation [13].

miRNAs can be engaged in the regulation of gene expression and induce protein translation inhibition by partially complementary combining with the 3′ noncoding region of the mRNA of downstream gene, thereby repressing protein synthesis [14, 15]. Bioinformatics analysis demonstrated that microRNA-146-5p could regulate the expression of ubiquitin specific protease 3 (USP3) and bind to it specifically. USP3 is a member of the ubiquitin specific protease (USP) family, which can bind to its target protein through a series of steps by acting on a highly conserved small molecule protein—ubiquitin, mediating the degradation of the target protein or causing other corresponding biological effects [16, 17]. In addition, the research of ubiquitin-specific proteases in diseases is increasingly deepening, including neurodegenerative diseases, hematologic diseases, and infectious diseases, which may serve as a new treatment method for PAH and other diseases in the near future [18, 19].

In this study, we first explored the expression of microRNA-146-5p and USP3 and the interaction between them in pulmonary artery smooth muscle cells under hypoxia conditions, so as to clarify the impacts of microRNA-146-5p and USP3 in the progression and formation of PAH, which may provide a new target for the diagnosis and treatment of PAH.

2. Patients and Methods

2.1. Clinical Samples. Serum samples from 30 PAH patients aged 36.70 ± 10.31 and 20 healthy volunteers aged 33.02 ± 8.52 were collected and stored in a refrigerator at -80°C. Patients diagnosed with PAH should meet the published guidelines for the diagnosis of pulmonary hypertension: (1) mPAP ≥ 25 mmHg at rest, (2) pulmonary artery wedge pressure ≤ 15 mmHg, and (3) pulmonary vascular resistance (PVR) > 3 Wood units. Patients were excluded if associated with a definite cause, including connective tissue disease, congenital heart disease, chronic pulmonary thromboembolism, and PAH due to left heart disease, lung diseases, and hypoxemia [20–22]. According to the guidelines of the Helsinki Declaration, all subjects in this research signed informed consent, which was approved by the Ethics Committee of Tianjin Chest Hospital. This study was conducted in accordance with the Declaration of Helsinki.

2.2. Cell Culture. Human pulmonary artery endothelial cell lines (HPAEcs) and human renal epithelial cell line (293T) were purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA), and Dulbecco’s modified eagle medium (DMEM) and fetal bovine serum (FBS) were purchased from Life Technologies (Gaithersburg, MD, USA). All cells were cultured with high glucose DMEM containing 10% FBS, penicillin (100 U/mL), and streptomycin (100 μg/mL) in a 37°C, 5% CO₂ incubator. When grown to 80%-90% confluence, cells were digested with 1x trypsin +EDTA (ethylenediaminetetraacetic acid).

2.3. Transfection and Hypoxic Treatment. The control group (miR-NC) and the overexpression vector (microRNA-146-5p mimics) containing the microRNA-146-5p lentiviral sequence were purchased from Shanghai Jima Company (Shanghai, China). Cells were plated in 6-well plates and grown to a cell density of 30-40%, and lentiviral transfection was performed according to the manufacturer’s instructions. Cells were collected 48 h later for quantitative real-time polymerase chain reaction (qPCR) and Western blot experiments. In addition, HPAEC cells were exposed to hypoxia (1% O₂ and 5% CO₂) at 37°C.

2.4. Cell Proliferation Assays. The transfected cells were collected and plated into 96-well plates at 2000 cells per well. After cultured for 24h, 48h, 72h, and 96h, respectively, 10μL of cell counting kit-8 (CCK-8) solution (Dojindo, Kumamoto, Japan) was added per well for incubation for 2 hours, and then, the optical density (OD) value of each well was measured in the microplate reader at 490 nm absorption wavelength.

2.5. 5-Ethynyl-2′-Deoxyuridine (EdU) Assay. To assess the proliferative capacity of HPAEC cells, EdU proliferation assay (RiboBio, Guangzhou, China) was performed. After transfection for 24h, the cells were incubated with 50 μm EDU for 2 h, then stained with AdoLo and 4′,6-diamidino-2-phenylindole (DAPI), and the number of EDU-positive cells was examined by fluorescence microscopy. The display rate of EDU positive was shown as the ratio of the number of EDU positive cells to the total DAPI chromogenic cells (blue cells).

2.6. Real-Time PCR. Total RNA was extracted from HPAEC cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed into complementary deoxyribonucleic acid (cDNA) using Primerscript RT Reagent. qPCR reactions were performed using SYBR® Premix Ex TaqTM (TaKaRa, Tokyo, Japan) and StepOne Plus Real-time PCR System. The following primers were used for qPCR reaction:

- microRNA-146-5p: forward: 5′-GGCCTCTGTGACTCTTACTC-3′, reverse: 5′-GCCCTCTGTGACTTACTC-3′;
- U6: forward: 5′-GCCCTCTGTGACTTACTC-3′, reverse: 5′-GCCCTCTGTGACTTACTC-3′;
- USP3: forward: 5′-GCCCTCTGTGACTTACTC-3′, reverse: 5′-GCCCTCTGTGACTTACTC-3′;
- USP3: forward: 5′-GCCCTCTGTGACTTACTC-3′, reverse: 5′-GCCCTCTGTGACTTACTC-3′;
- USP3: forward: 5′-GCCCTCTGTGACTTACTC-3′, reverse: 5′-GCCCTCTGTGACTTACTC-3′;
- USP3: forward: 5′-GCCCTCTGTGACTTACTC-3′, reverse: 5′-GCCCTCTGTGACTTACTC-3′;
- USP3: forward: 5′-GCCCTCTGTGACTTACTC-3′, reverse: 5′-GCCCTCTGTGACTTACTC-3′.

Data analysis was performed using the ABI Step One software (Applied Biosystems, Foster City, CA, USA), and the relative expression levels of mRNA were calculated using the 2-ΔΔCT method [23].

2.7. Western Blot. The transfected cells were lysed using cell lysis buffer and centrifuged at 14,000 × g for 15 minutes at 4°C. Total protein concentration was calculated by bicinchoninic acid (BCA) Protein Assay Kit (Pierce, Rockford, IL, USA). The extracted proteins were separated using a 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and subsequently transferred to a polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica,
Western blot analysis was performed according to standard procedures. The primary antibody against USP3 (23303S) and the internal reference GAPDH (5174T) and the secondary antibody were both purchased from Cell Signaling Technology (Danvers, MA, USA).

2.8. Dual-Luciferase Reporter Assay. 293T cells were seeded in 24-well plates and cotransfected with microRNA-146-5p mimic/NC and pMIR luciferase reporter plasmids. Prior to this, the plasmid was ligated into the pMIR by insertion of other wild-type USP3, paired with the 3′UTR of the USP3 mutation binding site. The plasmid was then introduced into the cells using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. After 48 hours of transfection, the reporter luciferase activity was normalized to the control firefly luciferase activity.

2.9. Statistical Analysis. The program was processed using the Statistical Product and Service Solutions (SPSS) 22.0 program (IBM, Armonk, NY, USA), and the data were expressed as mean ± standard deviation. \( p < 0.05 \) was
considered to be statistically significant. The continuity variable was analyzed by t-test, and the categorical variable was analyzed by χ² test or Fisher’s exact probability method.

3. Results

3.1. MicroRNA-146-5p and USP3 Expression in Plasma of Patients with PAH. QPCR detected that PAH patient serum contained higher microRNA-146-5p expression and lower USP3 expression compared to the healthy volunteers (p < 0.05; Figures 1(a) and 1(b)).

3.2. Hypoxia Decreased MicroRNA-146-5p While Increased USP3 Expression in HPAECs. To determine microRNA-146-5p and USP3 expression in HPAECs under hypoxic conditions, we cultured HPAECs under hypoxic conditions for 0, 24, 48, and 72 h, respectively, and found a dramatic reduction in microRNA-146-5p expression in a time-dependent manner (Figure 2(a)). In addition, USP3 expression was relatively shown as 2.02 ± 0.16, 3.38 ± 0.16, and 3.35 ± 0.42 at 24 hours, 48 hours, and 72 hours, respectively, measured by Western blot assay, suggesting that hypoxia could dramatically induce USP3 protein expression in HPAECs (Figure 2(b)).

3.3. MicroRNA-146-5p Upregulation Accelerates Proliferation Rate of HPAECs. The microRNA-146-5p overexpression vector was constructed to further evaluate how microRNA-146-5p promotes the growth of HPAECs under hypoxic conditions. After 24 hours of transfection and 48
hours of exposure to hypoxia, qPCR detected an increased microRNA-146-5p level in HPAEC cells induced by overexpression of microRNA-146-5p compared to miR-NC, suggesting a successful construction model (Figure 3(a)). Subsequently, CCK-8 and EdU assays indicated that microRNA-146-5p overexpression dramatically enhanced the proliferation capacity of HPAECs exposed in hypoxia for 48 h compared to the control group (Figures 3(b) and 3(c)).

3.4. USP3 Is a Target of MicroRNA-146-5p. Bioinformatics predicted a potential binding site of microRNA-146-5p in USP3 3′-UTR (Figure 4(a)). And luciferase reporting assay verified that the luciferase activity of 293T cells transfected with WT-USP3-3′-UTR vector and microRNA-146-5p overexpression vector was dramatically attenuated after 48 h of hypoxia, while the cytoluciferase activity of cells transfected with MUT-USP3-3′-UTR was not affected (Figure 4(b)), which confirmed that microRNA-146-5p could directly target USP3 by binding to its 3′-UTR. In addition, overexpression of microRNA-146-5p reduced USP3 in HPAECs exposed in hypoxia for 48 h at both mRNA and protein levels (Figures 4(c) and 4(d)). The above data suggested that USP3 may act as a target for microRNA-146-5p in HPAECs under hypoxic conditions.

3.5. Overexpression of USP3 Partly Alleviates the Impacts of MicroRNA-146-5p on Cell Proliferation Ability of HPAECs under Hypoxia. To further elucidate the regulation of microRNA-146-5p and USP3 on HPAEC cell proliferation under hypoxic conditions, we transfected miR-NC + NC, microRNA-146-5p + NC, or microRNA-146-5p + USP3 into HPAEC cells, followed by hypoxia for 48 hours. qPCR analysis revealed a significant reduction of microRNA-146-5p expression in HPAEC cells transfected with microRNA-146-5p + USP3 compared to those transfected with microRNA-146-5p + NC (Figure 5(a)). In addition, the results of CCK-8 and EdU assays indicated that the proliferation ability of HPAECs in the microRNA-146-5p + USP3 group was dramatically weakened compared to the miR-NC + NC group; however, when compared with the miR-NC + NC group, after 48 h hypoxia, the cell proliferation ability was reversed (Figures 5(b) and 5(c)). Additionally, USP3 expression was significantly higher in the microRNA-146-5p + USP3 group than in the microRNA-146-5p + NC group (Figure 5(d)). The above data suggested that USP3 overexpression partially could attenuate the influence of microRNA-146-5p upregulation on cell proliferation capacity under hypoxia.

4. Discussion

Pulmonary arterial hypertension (PAH) is a disease typically characterized by pulmonary artery contraction, progressive pulmonary vascular resistance increase, and pulmonary artery pressure rise, which can lead to fatal right heart failure [1–4]. Pulmonary arterioles are composed of endothelial cells, smooth muscle cells, and fibroblasts [5–7]; among which, pulmonary smooth muscle cells are the main...
Figure 5: Overexpression of USP3 attenuates the effect of overexpression of miR-146-5p on the proliferative capacity of HPAEC cells after 48 h of hypoxic treatment. (a) qRT-PCR was used to detect the mRNA expression level of miR-146-5p in HPAEC cells after cotransfection of miR-146-5p and USP3 overexpression vectors after 48 h of hypoxia. (b) CCK-8 detected the proliferative capacity of HPAEC cells after cotransfection of miR-146-5p and USP3 overexpression vectors after 48 h of hypoxia. (c) The EdU assay detected the number of positive proliferating cells in HPAECs after cotransfection of miR-146-5p and USP3 overexpression vectors after 48 h of hypoxia. (d) Western blotting was used to detect the protein expression level of USP3 in HPAEC cells after cotransfection of miR-146-5p and USP3 overexpression vectors after 48 h of hypoxia. Data were mean ± SD, and * indicates a significant difference (p < 0.05).
biological effector cells in the contraction process of pulmonary arterioles caused by hypoxia and also the key cells involved in the structural reconstruction of pulmonary vessels under the condition of chronic hypoxia [7, 8].

MicroRNA (miRNA), a kind of short single-stranded RNA about 18-25bp in length, can mediate the physiological and pathological processes of almost all diseases, including cell proliferation, differentiation, migration, carcinogenesis, and apoptosis [9–11]. Previous studies uncover the key role of miRNAs in PAH. Recently, miR-182-3p/Myaedm contribute to pulmonary artery hypertension vascular remodeling via a KLF4/p21-dependent mechanism [24]. Besides, miR-483 might reduce experimental pulmonary hypertension by inhibition of multiple adverse responses [25]. In this study, compared with healthy volunteers, patients with PAH had a significant higher expression of microRNA-146-5p but a lower expression of USP3. Previous studies have shown that HPAECs play a crucial role in the process of hypoxia in vitro, including promoting cell proliferation and apoptosis, as well as enhancing cell secretion activity. In this investigation, after hypoxia for 24 h, 48 h, and 72 h in HPAEC cells, it was found that the expression of microRNA-146-5p was markedly downregulated while USP3 expression was conversely upregulated, in a time-dependent manner. In HPAEC cells, after overexpression of microRNA-146-5p, CCK-8 and EdU assay revealed an enhanced proliferation ability of HPAEC cells and an elevated positive rate of EdU staining with the increase of time after 48 h of hypoxia culture, suggesting that overexpression of microRNA-146-5p could promote the proliferation activity of pulmonary smooth muscle cells.

miRNA genes are usually located in intron regions, and single strand mature miRNA is produced through a series of processing processes. Mature miRNA molecules form RNA-induced silencing complex (RISC) with Dicer, Argonaute protein, etc. in cells and act on the 3′UTR of specific mRNA to inhibit the translation process or directly degrade the mRNA [11, 12]. For example, microRNA-146-5p could specifically bind to USP3, confirmed in our research by bioinformatics analysis and luciferase reporter gene assay. As a new target gene of microRNA-146-5p, USP3 is found as a member of ubiquitin specific protease (DUBs), which was initially discovered for its cDNA clone fragment had one or two conserved sequences consistent with DUBs. USP3, located on human chromosome 15q22.3, is a functional ubiquitin-specific protease that inhibits ubiquitin-dependent protein degradation [16, 17]. USP can also interact with its target protein through removing the ubiquitin molecules that bind to it, thereby inhibiting the degradation or mediating downstream biological functions of the target protein [18, 19]. In addition, USP3 was dramatically downregulated after the overexpression of microRNA-146-5p. However, under hypoxia conditions, simultaneous overexpression of microRNA-146-5p and USP3 reversed the enhanced proliferation ability induced by microRNA-146-5p. In this study, we firstly uncovered the role of miR-146-5p in PAH by in vitro assay; however, the in vivo assay should be added in the future study.

5. Conclusions
In summary, microRNA-146-5p can elevate the proliferation rate of HPAEC cells under hypoxia conditions by targeted modulating USP3, suggesting that microRNA-146-5p/USP3 axis may be a potential target for PAH treatment.

Data Availability
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest
The authors declared no conflict of interest.

References

[1] M. T. Harting, “Congenital diaphragmatic hernia-associated pulmonary hypertension,” *Seminars in Pediatric Surgery*, vol. 26, no. 3, pp. 147–153, 2017.

[2] M. M. Hoepfer, H. A. Ghofrani, E. Grunig, H. Klose, H. Olschewski, and S. Rosenkranz, “Pulmonary hypertension,” *Deutsches Arzteblatt International*, vol. 114, no. 5, pp. 73–84, 2017.

[3] H. Han, J. K. Francis, Y. Spitzer, and S. Reddy, “Anesthetic management of parturients with pulmonary hypertension undergoing cesarean deliveries,” *Journal of Clinical Anesthesia*, vol. 57, p. 79, 2019.

[4] A. Venkateshvaran, A. Manouras, B. Kjellstrom, and L. H. Lund, “The additive value of echocardiographic pulmonary to left atrial global strain ratio in the diagnosis of pulmonary hypertension,” *International Journal of Cardiology*, vol. 292, pp. 205–210, 2019.

[5] I. Cortés-Puch, J. Sun, A. N. Schechter et al., “Inhaled neu-

lized nitrite and nitrate therapy in a canine model of hypoxia-

induced pulmonary hypertension,” *Nitric Oxide*, vol. 91, pp. 1–

14, 2019.

[6] B. Cockbain, L. C. Price, and M. Hind, “Bony breathlessness,” *Circulation*, vol. 140, no. 10, pp. 880–885, 2019.

[7] S. Minatsuki, M. Hatano, H. Maki, E. Takimoto, H. Morita, and I. Komuro, “Analysis of oxygenation in chronic thrombo-

embolic pulmonary hypertension using dead space ratio and intrapulmonary shunt ratio,” *International Heart Journal*, vol. 60, no. 5, pp. 1137–1141, 2019.

[8] X. Cheng, Y. Wang, and L. Du, “Epigenetic modulation in the initiation and progression of pulmonary hypertension,” *Hypertension*, vol. 74, no. 4, pp. 733–739, 2019.

[9] S. R. Mousavi, A. Ahmadi, S. A. Jamalkandi, and J. Salimian, “Involvement of microRNAs in physiological and pathological processes in asthma,” *Journal of Cellular Physiology*, vol. 234, no. 12, pp. 21547–21559, 2019.

[10] A. Bahiraei, R. Ebrahimii, R. Halabian, A. S. Aghabozorgi, and J. Amani, “The role of inflammation and its related micro-

RNAs in breast cancer: a narrative review,” *Journal of Cellular Physiology*, vol. 234, no. 11, pp. 19480–19493, 2019.

[11] L. Fu and Q. Peng, “A deep ensemble model to predict miRNA-disease association,” *Scientific Reports*, vol. 7, no. 1, p. 14482, 2017.
C. Backes, E. Meese, and A. Keller, “Specific miRNA disease biomarkers in blood, serum and plasma: challenges and prospects,” *Molecular Diagnosis & Therapy*, vol. 20, no. 6, pp. 509–518, 2016.

A. R. Coffey, M. Kanke, T. L. Smallwood et al., "MicroRNA-146a-5p association with the cardiometabolic disease risk factor TMAO," *Physiological Genomics*, vol. 51, no. 2, pp. 59–71, 2019.

D. Wang, L. Xin, J. H. Lin et al., "Identifying miRNA-mRNA regulation network of chronic pancreatitis based on the significant functional expression," *Medicine*, vol. 96, no. 21, article e6668, 2017.

F. Afonso-Grunz and S. Muller, "Principles of miRNA-mRNA interactions: beyond sequence complementarity," *Cellular and Molecular Life Sciences*, vol. 72, no. 16, pp. 3127–3141, 2015.

X. Wu, M. Liu, H. Zhu et al., "Ubiquitin-specific protease 3 promotes cell migration and invasion by interacting with and deubiquitinating SUZ12 in gastric cancer," *Journal of Experimental & Clinical Cancer Research*, vol. 38, no. 1, p. 277, 2019.

Q. Zhou, Z. Xiao, R. Zhou et al., "Ubiquitin-specific protease 3 targets TRAF6 for deubiquitination and suppresses IL-1β induced chondrocyte apoptosis," *Biochemical and Biophysical Research Communications*, vol. 514, no. 2, pp. 482–489, 2019.

I. Cleynen, E. Vazeille, M. Artieda et al., "Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease," *Gut*, vol. 63, no. 8, pp. 1265–1274, 2014.

C. L. Fang, C. C. Lin, H. K. Chen et al., "Ubiquitin-specific protease 3 overexpression promotes gastric carcinogenesis and is predictive of poor patient prognosis," *Cancer Science*, vol. 109, no. 11, pp. 3438–3449, 2018.

N. Galíè, L. Rubin, M. Hoeper et al., "Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial," *Lancer*, vol. 371, no. 9630, pp. 2093–2100, 2008.

N. Galíè, M. Humbert, J. L. Vachiery et al., “2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT),” *European Heart Journal*, vol. 37, no. 1, pp. 67–119, 2016.

N. Galíè, M. Humbert, J. L. Vachiery et al., “2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension,” *Revista Española de Cardiología*, vol. 69, no. 2, p. 177, 2016.

K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔC−_T method," *Methods*, vol. 25, no. 4, pp. 402–408, 2001.

L. Sun, P. Lin, Y. Chen et al., “MiR-182-3p/Myadm contribute to pulmonary artery hypertension vascular remodeling via a KLF4/p21-dependent mechanism,” *Theranostics*, vol. 10, no. 12, pp. 5581–5599, 2020.

J. Zhang, Y. He, X. Yan et al., “MicroRNA-483 amelioration of experimental pulmonary hypertension,” *EMBO Molecular Medicine*, vol. 12, no. 5, article e11303, 2020.